Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty ?. Results of the MERCATOR study : a multicenter, randomized, double-blind placebo-controlled trial

Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty ?. Results of the MERCATOR study : a multicenter, randomized, double-blind placebo-controlled trial

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Circulation (New York, N.Y.) N.Y.), 1992-07, Vol.86 (1), p.100-110
Format: Artikel
Sprache:eng
Schlagworte:
Biological and medical sciences
Cardiovascular system
Medical sciences
Pharmacology. Drug treatments
Vascular wall
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 110
container_issue 1
container_start_page 100
container_title Circulation (New York, N.Y.)
container_volume 86
description
format Article
fullrecord <record><control><sourceid>pascalfrancis</sourceid><recordid>TN_cdi_pascalfrancis_primary_5433043</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>5433043</sourcerecordid><originalsourceid>FETCH-LOGICAL-p182t-b7c11addd26b07399179fbff377664d59271619b1886b002727a49c477bbea063</originalsourceid><addsrcrecordid>eNotUEtLAzEQXkTB-vgPc_DYlc2-0vUiUusDFKHoWSbJrI1kkyXJKu1f9k8YrIdhGGbmex1kM9aUdV43VXeYzYqi6HJeleVxdhLCZxrbijez7OfWUYC4IbD0DWg_tItkg7Ygnf0iH7X9ALK77UCg7UYLHZ0HqQ3ucPTawOjpi2wETyE9uqADYB_Jw0heThEtuSkReLTBTIO2aBKydxb9dk83GgxxC9eXsKYwmRjA9X-Cnlfr5c3ryxpCnNQWrgBhSHstEx35OSRI5Qa9IzUH5SZhKBdGWwUJUZJweXIQvTOGVOLXaM6yox5NoPP_fpq93a1elw_508v94_LmKR_Zooy54JIxVEqVrSh41XWMd73o-4rztq1V05WctawTbLFIB0XJS451J2vOhSBMuZ5mF3vcEYNE0yehUof3FNeQXL83dVUVqX4BrqyHXA</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty ?. Results of the MERCATOR study : a multicenter, randomized, double-blind placebo-controlled trial</title><source>American Heart Association Journals</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>CODEN: CIRCAZ</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams &amp; Wilkins</publisher><subject>Biological and medical sciences ; Cardiovascular system ; Medical sciences ; Pharmacology. Drug treatments ; Vascular wall</subject><ispartof>Circulation (New York, N.Y.), 1992-07, Vol.86 (1), p.100-110</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=5433043$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><title>Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty ?. Results of the MERCATOR study : a multicenter, randomized, double-blind placebo-controlled trial</title><title>Circulation (New York, N.Y.)</title><subject>Biological and medical sciences</subject><subject>Cardiovascular system</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Vascular wall</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><recordid>eNotUEtLAzEQXkTB-vgPc_DYlc2-0vUiUusDFKHoWSbJrI1kkyXJKu1f9k8YrIdhGGbmex1kM9aUdV43VXeYzYqi6HJeleVxdhLCZxrbijez7OfWUYC4IbD0DWg_tItkg7Ygnf0iH7X9ALK77UCg7UYLHZ0HqQ3ucPTawOjpi2wETyE9uqADYB_Jw0heThEtuSkReLTBTIO2aBKydxb9dk83GgxxC9eXsKYwmRjA9X-Cnlfr5c3ryxpCnNQWrgBhSHstEx35OSRI5Qa9IzUH5SZhKBdGWwUJUZJweXIQvTOGVOLXaM6yox5NoPP_fpq93a1elw_508v94_LmKR_Zooy54JIxVEqVrSh41XWMd73o-4rztq1V05WctawTbLFIB0XJS451J2vOhSBMuZ5mF3vcEYNE0yehUof3FNeQXL83dVUVqX4BrqyHXA</recordid><startdate>19920701</startdate><enddate>19920701</enddate><general>Lippincott Williams &amp; Wilkins</general><scope>IQODW</scope></search><sort><creationdate>19920701</creationdate><title>Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty ?. Results of the MERCATOR study : a multicenter, randomized, double-blind placebo-controlled trial</title></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p182t-b7c11addd26b07399179fbff377664d59271619b1886b002727a49c477bbea063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Biological and medical sciences</topic><topic>Cardiovascular system</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Vascular wall</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><collection>Pascal-Francis</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty ?. Results of the MERCATOR study : a multicenter, randomized, double-blind placebo-controlled trial</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><date>1992-07-01</date><risdate>1992</risdate><volume>86</volume><issue>1</issue><spage>100</spage><epage>110</epage><pages>100-110</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><coden>CIRCAZ</coden><cop>Hagerstown, MD</cop><pub>Lippincott Williams &amp; Wilkins</pub><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0009-7322
ispartof Circulation (New York, N.Y.), 1992-07, Vol.86 (1), p.100-110
issn 0009-7322
1524-4539
language eng
recordid cdi_pascalfrancis_primary_5433043
source American Heart Association Journals; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals
subjects Biological and medical sciences
Cardiovascular system
Medical sciences
Pharmacology. Drug treatments
Vascular wall
title Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty ?. Results of the MERCATOR study : a multicenter, randomized, double-blind placebo-controlled trial
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T13%3A57%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pascalfrancis&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Does%20the%20new%20angiotensin%20converting%20enzyme%20inhibitor%20cilazapril%20prevent%20restenosis%20after%20percutaneous%20transluminal%20coronary%20angioplasty%20?.%20Results%20of%20the%20MERCATOR%20study%20:%20a%20multicenter,%20randomized,%20double-blind%20placebo-controlled%20trial&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.date=1992-07-01&rft.volume=86&rft.issue=1&rft.spage=100&rft.epage=110&rft.pages=100-110&rft.issn=0009-7322&rft.eissn=1524-4539&rft.coden=CIRCAZ&rft_id=info:doi/&rft_dat=%3Cpascalfrancis%3E5433043%3C/pascalfrancis%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true